Sélection de la langue

Gouvernement du Canada / Government of Canada

Recherche

Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy

DOITrouver le DOI : https://doi.org/10.1007/978-1-59745-169-7_3
AuteurRechercher : ; Rechercher : 1Identifiant ORCID : https://orcid.org/0000-0002-0665-7041
Affiliation
  1. Conseil national de recherches Canada. Institut des biosciences marines du CNRC
FormatTexte, Chapitre de livre
Sujetcancer; protein tyrosine kinases; targeted therapy; proteomics
Résumé
Protein tyrosine kinases (PTKs) and their substrates are emerging as attractive therapeutic targets and potential biomarkers for molecular classifications, prediction of clinical outcome and monitoring response to cancer treatments. The exciting move toward kinase-targeted therapy has brought new technical challenges in profiling protein kinase genes and proteins as surrogate clinical biomarkers, particularly in light of clinical data correlating specific mutations in PTKs with either sensitivity or resistance to targeted therapy. This chapter discusses the impact of mutations on protein conformation, protein phosphorylation, and drug response and the utility of proteomic technology to mine the phosphoproteome for PTK profiling and prediction of response to targeted therapies.
Date de publication
Maison d’éditionHumana Press
Dans
  • Cancer Proteomics (2008) : 59–77.
Langueanglais
Publications évaluées par des pairsOui
Exporter la noticeExporter en format RIS
Signaler une correctionSignaler une correction (s'ouvre dans un nouvel onglet)
Identificateur de l’enregistrement481833ce-d08b-460c-a319-5a5f8783fd8b
Enregistrement créé2024-07-05
Enregistrement modifié2024-07-05

Détails de la page

Par :

Date de modification :